Novartis says Signifor LAR drug helps control acromegaly disease in last trial
ZURICH - Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly than existing ...